/BIOPOR.CO
BIOPOR.CO Stock - BioPorto A/S
Healthcare|Medical - Diagnostics & ResearchCPH
$1.04+0.39%
+$0.00 (+0.39%) • Dec 23
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.7
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.14
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BIOPOR.CO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.03 – $1.05
TARGET (TP)$1.20
STOP LOSS$0.96
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.31
52W High$1.77
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $36.24M | $30.96M | $28.97M | $24.25M | $23.20M |
| Gross Profit | $24.53M | $20.18M | $19.04M | $15.04M | $13.34M |
| Gross Margin | 67.7% | 65.2% | 65.7% | 62.0% | 57.5% |
| Operating Income | $-75,452,000 | $-60,164,000 | $-77,876,000 | $-65,255,000 | $-63,590,000 |
| Net Income | $-68,243,000 | $-56,328,000 | $-75,923,000 | $-57,113,000 | $-61,562,000 |
| Net Margin | -188.3% | -181.9% | -262.1% | -235.5% | -265.3% |
| EPS | $-0.17 | $-0.16 | $-0.23 | $-0.21 | $-0.29 |
Company Overview
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BIOPOR.COBeat Rate
27%
Last 15 quarters
Avg Surprise
-6.9%
EPS vs Estimate
Beats / Misses
4/8
3 met exactly
Latest EPS
$-0.05
Q4 2025
EPS Surprise History
Q1 24
-33.3%
$-0.02vs$-0.01
Q2 24
-33.3%
$-0.04vs$-0.03
Q3 24
-33.3%
$-0.04vs$-0.03
Q4 24
0.0%
$-0.05vs$-0.05
Q1 25
No data
Q2 25
-20.0%
$-0.06vs$-0.05
Q3 25
-0.8%
$-0.04vs$-0.04
Q4 25
-28.2%
$-0.05vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | $-0.04 | $-0.05 | -28.2% | ✗ MISS |
Q3 2025 | Aug 15, 2025 | $-0.04 | $-0.04 | -0.8% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q1 2025 | Jan 6, 2025 | — | $-0.04 | — | — |
Q4 2024 | Nov 14, 2024 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2024 | Aug 15, 2024 | $-0.03 | $-0.04 | -33.3% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.03 | $-0.04 | -33.3% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $-0.01 | $-0.02 | -33.3% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $-0.02 | $-0.03 | -25.0% | ✗ MISS |
Q3 2023 | Aug 1, 2023 | $-0.05 | $-0.06 | -20.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.05 | $-0.05 | 0.0% | = MET |
Q4 2022 | Dec 31, 2022 | — | $-0.07 | — | — |
Q4 2022 | Nov 9, 2022 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Q3 2022 | Aug 17, 2022 | $-0.05 | $-0.05 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.06 | — | — |
Q4 2021 | Nov 18, 2021 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q3 2021 | Aug 18, 2021 | $-0.06 | $-0.05 | +16.7% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about BIOPOR.CO
What is BIOPOR.CO's current stock price?
BioPorto A/S (BIOPOR.CO) is currently trading at $1.04 per share. The stock has moved +0.39% today.
What is the analyst price target for BIOPOR.CO?
No analyst price targets are currently available for this stock.
What sector is BioPorto A/S in?
BioPorto A/S operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the CPH exchange.
What is BIOPOR.CO's market cap?
BioPorto A/S has a market capitalization of $0.47 billion, making it a small-cap company.
Does BIOPOR.CO pay dividends?
No, BioPorto A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBRAINP.CO
Brain+ A/S
$0.01
Mkt Cap: $0.0B
MONSO.CO
Monsenso A/S
$0.16
Mkt Cap: $0.0B
PEG.CO
Pharma Equity Group A/S
$0.09
Mkt Cap: $0.1B
SMSMED.CO
Scandinavian Medical Solutions A/S
$4.75
Mkt Cap: $0.1B
STENO.CO
Stenocare A/S
$1.47
Mkt Cap: $0.1B
VIRO.CO
ViroGates A/S
$12.05
Mkt Cap: $0.1B
Explore stocks similar to BIOPOR.CO for comparison